Furthermore, treatment of targeted drugs‐resistant HCC with adeno‐associated virus (AAV) targeting MCB1 or a proteasome inhibitor restores targeted drug response, suggesting their clinical significance in HCC combinational therapy. The gene discussed is PSMD4; the disease is hepatocellular carcinoma.